secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2026-08-19T20:15:13+00:00
Accession:  0001193125-26-356915
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health Q2 2026 revenue down 59% YoY; net loss widens to $12.7M
---------------------------------------------------------------------

- Total net revenue $1.225M vs $2.979M in Q2 2025 (-59%); product revenue down 60% to $1.18M.
- Net loss attributable to common stockholders $12.69M vs $10.41M; EPS -$15.68 vs -$358.94.
- Sales/marketing expense fell $2.5M after Future Pak licensing Jan 12, 2026; cost of product revenue rose to ~$1.0M.
- MVID NDA package expected ready end-2026; submission planned Q2 2027; crofelemer MVID data showed parenteral support reduction up to 48%.
- Non-GAAP recurring EBITDA loss widened to $8.4M; loss on debt extinguishment $3.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000119312526356915/0001193125-26-356915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000119312526356915/d380271d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-356915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer